Artwork

Innhold levert av Andrew Musgrave. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Andrew Musgrave eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

AMPLIA THERAPEUTICS LTD (ATX) - Pioneering Cancer Treatment: CEO & MD, Dr. Chris Burns on FAK Inhibitors, Pancreatic Cancer Breakthroughs, and the ACCENT Trial's Promise

12:32
 
Del
 

Manage episode 445494735 series 3570035
Innhold levert av Andrew Musgrave. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Andrew Musgrave eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Send us a text

Get ready to explore the cutting-edge world of cancer treatment with Dr. Chris Burns, CEO & MD of Amplia Therapeutics Limited and co-recipient of the 2024 Prime Minister's Prize for Innovation. Our latest episode of ASX Briefs takes you inside Amplia's groundbreaking work with Focal Adhesion Kinase (FAK) inhibitors, specifically their promising small molecule inhibitor, designed to tackle pancreatic cancer head-on. Dr. Burns shares the significant milestones in their ACCENT trial, including the recruitment of the first 26 patients and the remarkable achievement of six confirmed partial responses, which may signal a new frontier in cancer therapy.
Join us as Dr. Burns uncovers the science behind Amplia's innovative approach and how their treatment aims to enhance the effectiveness of existing therapies. He discusses the trial's progress, the potential for improved patient outcomes, and the exciting path forward with further recruitment underway. This episode is a compelling listen for anyone passionate about the future of oncology and the relentless pursuit of breakthroughs in cancer treatment. Don't miss the chance to hear firsthand from a leader at the forefront of medical innovation.

  continue reading

91 episoder

Artwork
iconDel
 
Manage episode 445494735 series 3570035
Innhold levert av Andrew Musgrave. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Andrew Musgrave eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Send us a text

Get ready to explore the cutting-edge world of cancer treatment with Dr. Chris Burns, CEO & MD of Amplia Therapeutics Limited and co-recipient of the 2024 Prime Minister's Prize for Innovation. Our latest episode of ASX Briefs takes you inside Amplia's groundbreaking work with Focal Adhesion Kinase (FAK) inhibitors, specifically their promising small molecule inhibitor, designed to tackle pancreatic cancer head-on. Dr. Burns shares the significant milestones in their ACCENT trial, including the recruitment of the first 26 patients and the remarkable achievement of six confirmed partial responses, which may signal a new frontier in cancer therapy.
Join us as Dr. Burns uncovers the science behind Amplia's innovative approach and how their treatment aims to enhance the effectiveness of existing therapies. He discusses the trial's progress, the potential for improved patient outcomes, and the exciting path forward with further recruitment underway. This episode is a compelling listen for anyone passionate about the future of oncology and the relentless pursuit of breakthroughs in cancer treatment. Don't miss the chance to hear firsthand from a leader at the forefront of medical innovation.

  continue reading

91 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2025 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett
Lytt til dette showet mens du utforsker
Spill